Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Filippo Spriano, Gaetanina Golino, PhD, Lorenzo Scalise, Emanuele Zucca, MD, Anastasios Stathis, MD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD, Francesco Bertoni, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-134664

Published: 2020

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Francesca Guidetti, Alessio Bruscaggin, PhD, Marco Frigeni, MD, Valeria Spina, PhD, Lodovico Terzi di Bergamo, Adalgisa Condoluci, MD, Gabriela Forestieri, Francesco Bertoni, MD, Luciano Cascione, PhD, Manuela Mollejo, Véronique Meignin, Alexandra Traverse-Glehen, MD PhD, Julia T Geyer, MD, Alessandro Broccoli, Alessandra Tucci, Silvia Bea, Renzo Boldorini, Gustavo Tapia, Antonino Maiorana, Maria Gomes da Silva, MD, Juan F. Garcia, Felicitas Hitz, Michele Merli, MD, Giorgio A. Vanini, Urban Novak, Francesco Piazza, Stefano Pizzolitto, Sascha Dietrich, Liliana Devizzi, Marco Ladetto, Maurilio Ponzoni, MD, Alessandro Rambaldi, MD, Paolo Corradini, Corrado Tarella, Elisa Santambrogio, Umberto Vitolo, Francesco Zaja, Francesco Passamonti, MD, Alexandar Tzankov, Sergio Cogliatti, Carlos Montalban, Roberto Marasca, MD, Laurence de Leval, MD, Carlo Visco, Maria Joao Baptista, PhD PharmD, Vincenzo Canzonieri, Estella Matutes, Fabio Facchetti, Marco Paulli, Elias Campo, David Oscier, Elena Sabattini, Pier Luigi Zinzani, MD, Govind Bhagat, Stefano A. Pileri, MD PhD, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, Gilles Salles, MD PhD, Catherine Thieblemont, MD, Miguel A. Piris, Franco Cavalli, MD, Emanuele Zucca, Luca Arcaini, MD, Davide Rossi, MD PhD

Blood (2018) 132 (Supplement 1): 922.

https://doi.org/10.1182/blood-2018-99-115958

Published: 2018

Journal Articles

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Blood (2018) 132 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2018-99-112763

Published: 2018

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Binu K Sasi, PhD, Sven Turkalj, BS, Hilal Kalkan, BS, Fabiola Porro, MS, Engin Bojnik, PhD, Beata Pyrzynska, PhD, Abdessamad Zerrouqi, PhD, Malgorzata Bobrowicz, PhD, Magdalena Winiarska, PhD, Valdemar Priebe, MS, Francesco Bertoni, MD, Larry Mansouri, PhD, Richard Rosenquist, MD PhD, Dimitar G Efremov, MD PhD

Blood (2018) 132 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2018-99-118120

Published: 2018

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 307.

https://doi.org/10.1182/blood.V130.Suppl_1.307.307

Published: 2017

Journal Articles

Plasma Cell Disease Genotyping with the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 327.

https://doi.org/10.1182/blood.V130.Suppl_1.327.327

Published: 2017

Journal Articles

ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma

Elaine Y Chung, PhD, Maurilio Ponzoni, MD, Zijun Yidan Xu-Monette, PhD, Valdemar Priebe, Luciano Cascione, PhD, Eugenio Gaudio, PhD, Emanuele Zucca, Davide Rossi, MD PhD, Ken H. Young, MD PhD, Francesco Bertoni, MD

Blood (2016) 128 (22): 1755.

https://doi.org/10.1182/blood.V128.22.1755.1755

Published: 2016

Journal Articles

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Petra Hillmann, Filippo Spriano, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Anastasios Stathis, Emanuele Zucca, Doriano Fabbro, Vladimir Cmiljanovic, Francesco Bertoni, MD

Blood (2016) 128 (22): 3017.

https://doi.org/10.1182/blood.V128.22.3017.3017

Published: 2016

Journal Articles

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

Katayoun Jessen, PhD, Eric Moseley, PhD, Elaine Yee Lin Chung, PhD, Lauren Otuski, BS, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, James Breitmeyer, MD PhD, James Freddo, MD, Jeffrey Toretsky, MD, Francesco Bertoni, MD, Brian J Lannutti, PhD

Blood (2016) 128 (22): 4035.

https://doi.org/10.1182/blood.V128.22.4035.4035

Published: 2016

Journal Articles

Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways

Blood (2016) 128 (22): 4096.

https://doi.org/10.1182/blood.V128.22.4096.4096

Published: 2016

Journal Articles

Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)

Andrea Rinaldi, PhD, Simone Ferrero, Ivo Kwee, PhD, Davide Rossi, MD PhD, Alessio Bruscaggin, Valeria Spina, Fary Diop, Filippo Ballerini, MD, Filippo Gherlinzoni, MD, Fabio Benedetti, Michael Mian, MD, Caterina Stelitano, MD, Elisa Doni, MD, Alessandra Flavia Salvi, Sergio Cortelazzo, Marco Ladetto, MD, Gianluca Gaidano, MD PhD, Francesco Bertoni, MD

Blood (2016) 128 (22): 4099.

https://doi.org/10.1182/blood.V128.22.4099.4099

Published: 2016

Journal Articles

The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents

Eugenio Gaudio, PhD, Ivo Kwee, PhD, Filippo Spriano, Chiara Tarantelli, PhD, Andrea Rinaldi, PhD, Thibaud Jourdan, Melanie Berthold, Alberto Arribas, PhD, Anastasios Stathis, Davide Rossi, MD PhD, Martin Lange, PhD, Oliver Politz, Emanuele Zucca, Francesco Bertoni, MD

Blood (2016) 128 (22): 4185.

https://doi.org/10.1182/blood.V128.22.4185.4185

Published: 2016

Journal Articles

Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma

Alberto Arribas, PhD, Eugenio Gaudio, PhD, Luca Arcaini, MD, Anastasios Stathis, Emanuele Zucca, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2016) 128 (22): 4186.

https://doi.org/10.1182/blood.V128.22.4186.4186

Published: 2016

Journal Articles

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Alberto Arribas, PhD, Luciano Cascione, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Maurilio Ponzoni, MD, Roberta Pittau Bordone, Georg Stussi, MD, Davide Rossi, MD PhD, Emanuele Zucca, Anastasios Stathis, Callum Sloss, PhD Molecular Biology, Francesco Bertoni, MD

Blood (2016) 128 (22): 4187.

https://doi.org/10.1182/blood.V128.22.4187.4187

Published: 2016

Journal Articles

Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations

Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Michela Boi, PhD, Elena Bernasconi, B.Sc., Monica Testoni, B.Sc., Anastasios Stathis, MD, Patrice Herait, MD, Kay Noel, PhD, Giorgio Inghirami, Emanuele Zucca, MD, Francesco Bertoni, MD

Blood (2013) 122 (21): 3070.

https://doi.org/10.1182/blood.V122.21.3070.3070

Published: 2013

NARROW

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Plasma Cell Disease Genotyping with the Liquid Biopsy

ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways

The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents

Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only